Published in PLoS One on May 02, 2014
A Polyglot Approach to Bioinformatics Data Integration: A Phylogenetic Analysis of HIV-1. Evol Bioinform Online (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2. J Virol (1972) 11.71
RNA interference--2001. Genes Dev (2001) 7.68
Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA (2006) 7.46
RNAi: nature abhors a double-strand. Curr Opin Genet Dev (2002) 5.74
Structure of the herpes simplex virus capsid. Molecular composition of the pentons and the triplexes. J Mol Biol (1993) 3.92
Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins. J Virol (1994) 3.24
Liquid-crystalline, phage-like packing of encapsidated DNA in herpes simplex virus. Cell (1991) 3.20
Capsid assembly and DNA packaging in herpes simplex virus. Rev Med Virol (1997) 3.15
Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. J Virol (1993) 2.79
Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses. J Gen Virol (1994) 2.69
Assembly of VP26 in herpes simplex virus-1 inferred from structures of wild-type and recombinant capsids. Nat Struct Biol (1995) 2.51
Finding a needle in a haystack: detection of a small protein (the 12-kDa VP26) in a large complex (the 200-MDa capsid of herpes simplex virus). Proc Natl Acad Sci U S A (1994) 2.27
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
Multiple interactions control the intracellular localization of the herpes simplex virus type 1 capsid proteins. J Gen Virol (1996) 1.96
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
Cell-free assembly of the herpes simplex virus capsid. J Virol (1994) 1.90
Assembly of the herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes. J Virol (1995) 1.84
Replication of herpes simplex virus DNA. J Biol Chem (1999) 1.77
Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother (2010) 1.73
The size and symmetry of B capsids of herpes simplex virus type 1 are determined by the gene products of the UL26 open reading frame. J Virol (1994) 1.63
Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med (2008) 1.49
RNA silencing. Curr Biol (2002) 1.35
Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov (2003) 1.28
Therapeutic potential of RNA interference. N Engl J Med (2004) 1.27
Herpes simplex viruses: mechanisms of DNA replication. Cold Spring Harb Perspect Biol (2012) 1.21
Functional analysis of the triplex proteins (VP19C and VP23) of herpes simplex virus type 1. J Virol (2006) 1.15
Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis (1995) 1.13
ATP-Dependent localization of the herpes simplex virus capsid protein VP26 to sites of procapsid maturation. J Virol (2000) 1.08
Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis (1990) 1.02
A cultured affair: HSV latency and reactivation in neurons. Trends Microbiol (2012) 0.98
Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis (2012) 0.93
Delivery systems and local administration routes for therapeutic siRNA. Pharm Res (2013) 0.92
Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children. J Clin Virol (2011) 0.91
Deletion or green fluorescent protein tagging of the pUL35 capsid component of pseudorabies virus impairs virus replication in cell culture and neuroinvasion in mice. J Gen Virol (2008) 0.91
Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J Virol (2004) 0.90
Analysis of the early steps of herpes simplex virus 1 capsid tegumentation. J Virol (2013) 0.85
Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA. Arch Virol (2008) 0.83
A domain in the herpes simplex virus 1 triplex protein VP23 is essential for closure of capsid shells into icosahedral structures. J Virol (2011) 0.83
Prevention, recognition and management of neonatal HSV infections. Expert Rev Anti Infect Ther (2012) 0.82
Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis. J Clin Virol (2013) 0.82
Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells. Clin Experiment Ophthalmol (2011) 0.80
Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J Clin Virol (2006) 0.79
Capsid assembly as a point of intervention for novel anti-viral therapeutics. Curr Pharm Biotechnol (2013) 0.78
Know-how of RNA interference and its applications in research and therapy. Mutat Res (2004) 0.78
A new nucleoside analogue with potent activity against mutant sr39 herpes simplex virus-1 (HSV-1) thymidine kinase (TK). Org Lett (2012) 0.76
Urotensin II promotes atherosclerosis in cholesterol-fed rabbits. PLoS One (2014) 0.81
Carbonate ion-enriched hot spring water promotes skin wound healing in nude rats. PLoS One (2015) 0.80
Motility and fertility of rabbit sperm cryopreserved using soybean lecithin as an alternative to egg yolk. Theriogenology (2015) 0.78
Production of Cloned Miniature Pigs Expressing High Levels of Human Apolipoprotein(a) in Plasma. PLoS One (2015) 0.77
AMPK Suppresses Connexin43 Expression in the Bladder and Ameliorates Voiding Dysfunction in Cyclophosphamide-induced Mouse Cystitis. Sci Rep (2016) 0.77
Bisphenol A exposure induces metabolic disorders and enhances atherosclerosis in hyperlipidemic rabbits. J Appl Toxicol (2015) 0.76
The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress. Biochem Biophys Res Commun (2014) 0.76
Bisphenol A exposure enhances atherosclerosis in WHHL rabbits. PLoS One (2014) 0.76
Combined B, T and NK Cell Deficiency Accelerates Atherosclerosis in BALB/c Mice. PLoS One (2016) 0.75
Hyperlipidemia-associated gene variations and expression patterns revealed by whole-genome and transcriptome sequencing of rabbit models. Sci Rep (2016) 0.75
Bre Enhances Osteoblastic Differentiation by Promoting the Mdm2-Mediated Degradation of p53. Stem Cells (2017) 0.75
Carbenoxolone inhibits TRPV4 channel-initiated oxidative urothelial injury and ameliorates cyclophosphamide-induced bladder dysfunction. J Cell Mol Med (2017) 0.75